Signals
4SignalNEWMay 8, 2026
Hyperemesis gravidarum therapy options widen past doxylamine-pyridoxine
Doxylamine-pyridoxine and ondansetron maturity, structured outpatient infusion pathways, and emerging GDF15-targeted programs are reshaping hyperemesis gravidarum management.
TreatmentPipelinePatient journeyInfrastructure
SignalNEWMay 8, 2026
Thyroid disease in pregnancy management formalises around structured monitoring
Pregnancy-specific TSH targets, structured pre-conception thyroid management, and integrated maternal-fetal medicine and endocrinology pathways are reshaping thyroid disease in pregnancy.
DiagnosisTreatmentPatient journeyInfrastructure
SignalNEWMay 7, 2026
Pelvic floor disorder therapy options widen past Kegel-and-surgery defaults
Pelvic floor physiotherapy formalisation, vibegron and emerging beta-3 agonist programs in overactive bladder, and integrated multidisciplinary care models are reshaping pelvic floor disorders.
TreatmentPatient journeyInfrastructureDelivery
SignalNEWMay 5, 2026
Breast cancer survivorship care widens past tamoxifen and aromatase inhibitor side-effect management
Vasomotor symptom therapy in breast cancer survivors, bone-health management with aromatase inhibitors, and structured survivorship programs are reshaping breast cancer survivorship care.
TreatmentPatient journeyInfrastructure